Oxaliplatin neurotoxicity

Roser Velasco, Jordi Bruna

Research output: Contribution to journalReview articleResearchpeer-review

8 Citations (Scopus)

Abstract

Oxaliplatin (OXA) is a first-line agent in the systemic treatment of colorectal cancer (CRC). OXA-induced neuropathy is the most prominent adverse effect, both during and after the completion of chemotherapy. OXA neurotoxicity (OXA-NTX) is a dose-limiting, frequent, and long-lasting adverse event that may compromise therapeutic outcome and the quality-of-life of CRC patients. Increased knowledge of the pathophysiology and clinical profile of this neuropathy is being achieved. Two types of neuropathy are usually observed, and evidence suggests a link between the acute symptoms and the development of chronic NTX. In this paper we review the main advances and the outstanding issues concerning OXA-NTX, for example calcium/magnesium and other drugs in the prophylaxis and treatment of this neuropathy. Recently available and ongoing investigation of pharmacogenomics, clinical and neurophysiological risk factors, and early markers of OXA-NTX are of great value in clinical decision-making, contributing to minimizing the risk of severe neuropathy. © 2014 Springer Science+Business Media.
Original languageEnglish
Pages (from-to)303-312
JournalCurrent Colorectal Cancer Reports
Volume10
Issue number3
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • CAPOX
  • Chemotherapy-induced neuropathy
  • Colorectal cancer
  • EORTC QLQ-CIPN20
  • FOLFOX
  • Nerve conduction studies
  • Neuropathy
  • Neurotoxicity
  • Oxalate
  • Oxaliplatin
  • Platinum compounds
  • Total neuropathy score
  • Voltage-gated sodium channel
  • XELOX

Fingerprint

Dive into the research topics of 'Oxaliplatin neurotoxicity'. Together they form a unique fingerprint.

Cite this